Use of sirolimus in the treatment of refractory autoimmune hepatitis

Hemant Chatrath, Larissa Allen, Thomas D Boyer

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND: Corticosteroids and azathioprine are widely accepted as the initial therapy for autoimmune hepatitis. However, the disease is refractory to steroids in about 10%-20% of patients, for whom currently there is no standardized treatment. Here we describe our experience with sirolimus in treatment of steroid refractory autoimmune hepatitis. METHODS: This is a longitudinal follow-up study. Between November 2007 and January 2014, 5 subjects with steroid refractory autoimmune hepatitis were treated with sirolimus at our institution. RESULTS: A response, defined as a sustained >50% fall in alanine aminotransferase (ALT) levels, was achieved in 4/5 patients. A complete response, sustained normalization of ALT levels, was achieved in 2/5 patients. The need for steroids was significantly reduced in all patients (P < .05). CONCLUSIONS: In this small series, sirolimus appears to be useful in the treatment of patients with steroid refractory autoimmune hepatitis.

Original languageEnglish (US)
Pages (from-to)1128-1131
Number of pages4
JournalAmerican Journal of Medicine
Volume127
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Autoimmune Hepatitis
Sirolimus
Steroids
Alanine Transaminase
Therapeutics
Azathioprine
Adrenal Cortex Hormones

Keywords

  • Autoimmune hepatitis
  • Sirolimus
  • Steroid-refractory

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of sirolimus in the treatment of refractory autoimmune hepatitis. / Chatrath, Hemant; Allen, Larissa; Boyer, Thomas D.

In: American Journal of Medicine, Vol. 127, No. 11, 01.11.2014, p. 1128-1131.

Research output: Contribution to journalArticle

Chatrath, Hemant ; Allen, Larissa ; Boyer, Thomas D. / Use of sirolimus in the treatment of refractory autoimmune hepatitis. In: American Journal of Medicine. 2014 ; Vol. 127, No. 11. pp. 1128-1131.
@article{a3e75f424cf84fd78031d7fdd59203fe,
title = "Use of sirolimus in the treatment of refractory autoimmune hepatitis",
abstract = "BACKGROUND: Corticosteroids and azathioprine are widely accepted as the initial therapy for autoimmune hepatitis. However, the disease is refractory to steroids in about 10{\%}-20{\%} of patients, for whom currently there is no standardized treatment. Here we describe our experience with sirolimus in treatment of steroid refractory autoimmune hepatitis. METHODS: This is a longitudinal follow-up study. Between November 2007 and January 2014, 5 subjects with steroid refractory autoimmune hepatitis were treated with sirolimus at our institution. RESULTS: A response, defined as a sustained >50{\%} fall in alanine aminotransferase (ALT) levels, was achieved in 4/5 patients. A complete response, sustained normalization of ALT levels, was achieved in 2/5 patients. The need for steroids was significantly reduced in all patients (P < .05). CONCLUSIONS: In this small series, sirolimus appears to be useful in the treatment of patients with steroid refractory autoimmune hepatitis.",
keywords = "Autoimmune hepatitis, Sirolimus, Steroid-refractory",
author = "Hemant Chatrath and Larissa Allen and Boyer, {Thomas D}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.amjmed.2014.06.016",
language = "English (US)",
volume = "127",
pages = "1128--1131",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Use of sirolimus in the treatment of refractory autoimmune hepatitis

AU - Chatrath, Hemant

AU - Allen, Larissa

AU - Boyer, Thomas D

PY - 2014/11/1

Y1 - 2014/11/1

N2 - BACKGROUND: Corticosteroids and azathioprine are widely accepted as the initial therapy for autoimmune hepatitis. However, the disease is refractory to steroids in about 10%-20% of patients, for whom currently there is no standardized treatment. Here we describe our experience with sirolimus in treatment of steroid refractory autoimmune hepatitis. METHODS: This is a longitudinal follow-up study. Between November 2007 and January 2014, 5 subjects with steroid refractory autoimmune hepatitis were treated with sirolimus at our institution. RESULTS: A response, defined as a sustained >50% fall in alanine aminotransferase (ALT) levels, was achieved in 4/5 patients. A complete response, sustained normalization of ALT levels, was achieved in 2/5 patients. The need for steroids was significantly reduced in all patients (P < .05). CONCLUSIONS: In this small series, sirolimus appears to be useful in the treatment of patients with steroid refractory autoimmune hepatitis.

AB - BACKGROUND: Corticosteroids and azathioprine are widely accepted as the initial therapy for autoimmune hepatitis. However, the disease is refractory to steroids in about 10%-20% of patients, for whom currently there is no standardized treatment. Here we describe our experience with sirolimus in treatment of steroid refractory autoimmune hepatitis. METHODS: This is a longitudinal follow-up study. Between November 2007 and January 2014, 5 subjects with steroid refractory autoimmune hepatitis were treated with sirolimus at our institution. RESULTS: A response, defined as a sustained >50% fall in alanine aminotransferase (ALT) levels, was achieved in 4/5 patients. A complete response, sustained normalization of ALT levels, was achieved in 2/5 patients. The need for steroids was significantly reduced in all patients (P < .05). CONCLUSIONS: In this small series, sirolimus appears to be useful in the treatment of patients with steroid refractory autoimmune hepatitis.

KW - Autoimmune hepatitis

KW - Sirolimus

KW - Steroid-refractory

UR - http://www.scopus.com/inward/record.url?scp=84912111078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912111078&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2014.06.016

DO - 10.1016/j.amjmed.2014.06.016

M3 - Article

C2 - 24979741

AN - SCOPUS:84912111078

VL - 127

SP - 1128

EP - 1131

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 11

ER -